Document is current
Any future updates will be listed below
-
Authors
Mascarella, Davide https://orcid.org/0000-0002-9265-3281
Andrini, Giorgia
Baraldi, Carlo https://orcid.org/0000-0001-8432-1888
Altamura, Claudia https://orcid.org/0000-0002-5934-5535
Favoni, Valentina https://orcid.org/0000-0001-5335-2438
Lo Castro, Flavia https://orcid.org/0000-0002-8572-3421
Pierangeli, Giulia
Vernieri, Fabrizio https://orcid.org/0000-0002-9594-9336
Guerzoni, Simona
Cevoli, Sabina https://orcid.org/0000-0003-4668-4295
-
Funding
Funding for this research was provided by:
Alma Mater Studiorum - Università di Bologna
- License Information
-
More Information
Article History
Received: 29 January 2024
Accepted: 27 April 2024
First Online: 25 May 2024
Declarations
:
: The study was approved by an independent ethics committee or local institutional review board at each participating site (protocol numbers: 20073, 50/2020/OSS/AOUMO and 625/2020/OSS/AUMO, and 30/20 OSS ComEt CBM, for the three participant centres). Written informed consent was obtained from all enrolled patients, both for study participation and data publication. All procedures were conducted according to the latest version of the Declaration of Helsinki.
: D. M. received travel grants from Ely Lilly; G.A.has no disclosure; C. A. received travel grants and honoraria from Novartis, Eli Lilly, Allergan, Lusofarmaco, and Laborest; S.C. and G.P. received travel grants, honoraria for advisory boards, speaker panels or clinical investigation studies from Novartis, Teva, Lilly, Allergan, Ibsa, andL undbeck; F.V. received travel grants, honoraria for advisory boards, and speaker panels from Allergan, Angelini, Lilly, Lundbeck, Novartis, and Teva; C.B. and S.G. received travel grants and honorary from Allergan, Novartis, Teva and ElyLilly; F.L. received travel grants and honoraria from Allergan/Abbvie, Eli Lilly.
